This review investigates the synthetic methods and anti-cancer activities of pyrazole compounds. Various synthetic approaches, including traditional organic synthesis and microwaveassisted synthesis, have been used to change the pyrazole core structure, resulting in new compounds with improved pharmacological properties. The paper also covers the mechanisms of action that underpin pyrazole derivatives' anti-cancer characteristics, focusing on interactions with major molecular targets implicated in cancer growth and proliferation. SAR insights help to rationally develop novel anti-cancer drugs. In conclusion, the review emphasizes the versatility of pyrazole derivatives as scaffolds for the discovery and development of new anti-cancer medicines. By understanding synthesis routes and unravelling anti-cancer potential, this study hopes to encourage new research endeavours focused on leveraging the therapeutic advantages of pyrazole paradigms in the fight against cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0115734064312273240429110026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC).
BMC Pulm Med
November 2024
Department of Oncology, the First Medical Center of PLA General Hospital, (Chinese PLA Key Laboratory of Oncology, Key Laboratory for Tumor Targeting Therapy and Antibody Drugs (Ministry of Education, China)), Beijing, 100853, China.
Article Synopsis
- - The study reviews advancements in research on RET rearrangements in solid tumors, specifically focusing on therapeutic strategies and outcomes in advanced non-small cell lung cancer (NSCLC) within China.
- - It analyzes the incidence of RET rearrangements, treatment approaches, and evaluates the effectiveness of targeted RET inhibitors, particularly assessing real-world patient outcomes.
- - A retrospective analysis of 64 patients shows that the KIF5B-RET fusion is the most common, with Pralsetinib achieving a median progression-free survival of 16.03 months, significantly better than chemotherapy.
Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review.
Int J Mol Sci
October 2024
Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.
Article Synopsis
- Rheumatoid arthritis (RA) patients experience unique challenges when infected with SARS-CoV-2 due to their immunocompromised status and treatments, which complicates their health outcomes compared to the general population.
- The systematic review, adhering to PRISMA guidelines, analyzed literature from 2021-2023 and highlighted issues such as delays in treatment due to COVID-19 fears and increased risk of severe outcomes tied to cardiovascular and metabolic conditions.
- Additionally, the review found that while COVID-19 vaccines are generally safe for RA patients, certain treatments like Methotrexate and Rituximab may weaken their vaccine response, emphasizing the need for tailored medical management during the pandemic.
Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.
Clin Transl Med
October 2024
Department of Medicine, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Article Synopsis
- The ROS1 proto-oncogene is linked with receptor tyrosine kinases and plays a significant role in treating ROS1 fusion-positive non-small cell lung cancer (NSCLC) using FDA-approved TKIs like crizotinib and entrectinib, though these medications face challenges such as resistance and limited brain penetration.
- Repotrectinib, a new macrocyclic TKI, was created to tackle resistance mutations and enhance brain distribution, showing strong effectiveness in the TRIDENT-1 trial with high response rates in both TKI-naïve and TKI-pretreated patients.
- The trial showed that 79% of TKI-naïve patients achieved an objective response and had longer progression
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care?
Expert Rev Hematol
November 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction: JAK inhibitors (JAKi) have changed the treatment paradigm of myelofibrosis (MF). Currently, 4 JAKis are approved in the US as monotherapy (mono) to treat patients with MF. JAKis are also being studied in combination (combo) with novel agents.
View Article and Find Full Text PDFArticle Synopsis
- Three generations of tyrosine kinase inhibitors (TKIs) exist for ALK fusion-positive non-small cell lung cancer, but they fail to effectively address resistance, brain activity, and TRK inhibition issues.* -
- NVL-655, a new TKI, shows superior selectivity and potency against ALK mutations, significantly outperforming current approved ALK TKIs in preclinical studies.* -
- Preliminary results from a phase I/II trial indicate NVL-655's promise for treating heavily pretreated patients, including those with brain metastases and resistance mutations, potentially making it a fourth-generation advancement for ALK-driven cancers.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!